Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125

Benzinga · 1d ago
Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $125.